Extracorporeal Membrane Oxygenation (ECMO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-11

Study Completion Date

2019-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since the 1970s, extracorporeal membrane oxygenation (ECMO) support has been used to support gas exchange for children with severe acute respiratory failure who fail mechanical ventilation. ECMO is more expensive than each of these other procedures.But its action is unclear

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extracorporeal Membrane Oxygenation for Respiratory Failure Patients

NCT06231446

Respiratory Failure Patients Treated With ECMO

RECRUITING

Establishment of a Early Risk Model of ECMO in Children With ARDS

NCT04710173

ARDS

COMPLETED

ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure

NCT04031794

Severe Acute Respiratory Distress Syndrome Refractory Hypoxemia

UNKNOWN

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

NCT01470703

Acute Respiratory Distress Syndrome (ARDS)

COMPLETED NA

Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

NCT06062212

Acute Respiratory Distress Syndrome Extracorporeal Membrane Oxygenation Mechanical Power +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since 1974, eight randomized controlled trials have been reported in ECMO for respiratory failure, and none have included non-neonatal pediatric patients. Cochrane systematic reviews of this evidence concluded that ECMO for neonatal respiratory failure had a survival advantage, but there was insufficient evidence to demonstrate a survival advantage for ECMO used to support respiratory failure in adults. Moreover, these trials were performed prior to 2009, and since then advances in ECMO technology have enhanced the delivery of ECMO support, and new research has changed conventional management of severe acute respiratory distress syndrome (ARDS)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extracorporeal Membrane Oxygenation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECMO

severe respiratory failure with ECMO

ECMO

Intervention Type DEVICE

the patients with severe respiratory failure were supported by ECMO

conventional mechanical ventilation

severe respiratory failure with conventional mechanical ventilation

conventional mechanical ventilation

Intervention Type DEVICE

the patients with severe respiratory failure were supported by conventional mechanical ventilation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECMO

the patients with severe respiratory failure were supported by ECMO

Intervention Type DEVICE

conventional mechanical ventilation

the patients with severe respiratory failure were supported by conventional mechanical ventilation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. ECMO group:

1. Oxygenation Index \> 40 for \>4 hours
2. Failure to wean from 100% oxygen despite prolonged (\> 48h) maximal medical therapy or persistent episodes of decompensation
3. Severe hypoxic respiratory failure with acute decompensation (PaO2 \<40) unresponsive to intervention
4. Severe pulmonary hypertension with evidence of right ventricular dysfunction and/or left ventricular dysfunction. The pulmonary artery pressure \> 60mmHg evaluated by the Echo, arterial duct keeps open and the blood flow was either by-level shunt or completely shunt from right side to left side.

2\. Non-ECMO group:

1. Oxygenation Index \> 16 and reach the Montreux definition of severe respiratory distress syndrome
2. Vasoactive-inotropic score (VIS) ≥ 40 \[VIS=dopamine dose (μg/kg/min)×1 + dobutamine dose (μg/kg/min)×1 + milrinone dose (μg/kg/min)×10 + amrinone dose (μg/kg/min)×10 + epinephrine dose (μg/kg/min)×100 + isoprenaline dose (μg/kg/min)×100\]

Exclusion Criteria

1. Gestational age \< 36 weeks, birth weight \< 2 kg, day post-birth \> 28 days.
2. lethal chromosomal disorder (includes trisomy 13, 18 but not 21) or any other lethal anomaly
3. irreversible brain damage
4. uncontrolled bleeding
5. Grade III or greater intraventricular hemorrhage
6. ventilator days ≥ 15 days.

Minimum Eligible Age

1 Hour

Maximum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

No